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Evolving Clinical Cancer Radiotherapy: Concerns Regarding 
Normal Tissue Protection and Quality Assurance
Radiotherapy, which is one of three major cancer treatment methods in modern medicine, 
has continued to develop for a long period, more than a century. The development of 
radiotherapy means allowing the administration of higher doses to tumors to improve 
tumor control rates while minimizing the radiation doses absorbed by surrounding normal 
tissues through which radiation passes for administration to tumors, thereby reducing or 
removing the incidence of side effects. Such development of radiotherapy was 
accomplished by the development of clinical radiation oncology, the development of 
computers and machine engineering, the introduction of cutting-edge imaging 
technology, a deepened understanding of biological studies on the effects of radiation on 
human bodies, and the development of quality assurance (QA) programs in medical 
physics. The development of radiotherapy over the last two decades has been quite 
dazzling. Due to continuous improvements in cancer treatment, the average five-year 
survival rate of cancer patients has been close to 70%. The increases in cancer patients’ 
complete cure rates and survival periods are making patients’ quality of life during or after 
treatment a vitally important issue. Radiotherapy is implemented in approximately 1/3 to 
2/3s of all cancer patients; and has improved the quality of life of cancer patients in the 
present age. Over the last century, as a noninvasive treatment, radiotherapy has 
unceasingly enhanced complete tumor cure rates and the side effects of radiotherapy have 
been gradually decreasing, resulting in a tremendous improvement in the quality of life of 
cancer patients.
Keywords: Radiotherapy; Normal Tissues; 2D-Radiotherapy; 3D-Conformal Radiotherapy; 
Radiotherapy, Intensity-Modulated; Heavy Ion Radiotherapy; Radiobiology; Quality 
Assurance, Health Care
Won Hoon Choi and Jaeho Cho
Department of Radiation Oncology, Yonsei 
University College of Medicine, Seoul, Korea
Received: 23 May 2015
Accepted: 23 October 2015
Address for Correspondence:
Jaeho Cho, MD
Department of Radiation Oncology, Yonsei University College of 
Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea
E-mail: jjhmd@yuhs.ac
Funding: This work was supported by the Nuclear Research and 
Development Program (NRF-2011-0031695) and the Radiation 
Technology Research and Development Program (NRF-
2013M2A2A7042978) through the National Research 
Foundation of Korea funded by the Ministry of Science, ICT & 
Future Planning and a faculty research grant from Yonsei 
University College of Medicine for 2014 (6-2014-0031). 
http://dx.doi.org/10.3346/jkms.2016.31.S1.S75 • J Korean Med Sci 2016; 31: S75-87
INTRODUCTION
The development of clinical radiation oncology means enhanc-
ing knowledge of the total radiation doses, fractional doses, and 
biological effective doses that are the most suitable for removal 
of certain tumors based on long experience in cancer patient 
radiotherapy (RT) at clinics. Many clinical articles and a deep-
ening of the knowledge of macroscopic and functional damage 
to normal organs around tumors occurring in the areas of clini-
cal RT doses have also contributed to the development of this 
field. This accumulation of knowledge of clinical radiation on-
cology per se plays an important role in effectively treating can-
cer while minimizing side effects. 
 However, even if necessary doses for tumor control and ef-
fects on surrounding normal organs were sufficiently under-
stood, the administration of accurate prescribed radiation dos-
es to tumors can be said to have been impossible without sup-
port by the development of physics, computers, and machine 
engineering. For instance, if radiation is prescribed to be gener-
ated at a point 100 cm away from the tumor in the body, it first 
has to pass through approximately 85 cm of air, then the skin of 
the chest, the hard ribs, and the lung tissues containing large 
amounts of air. Then, it has to be precisely focused to irradiate 
metastatic tumors in the lymph nodes in front of the thoracic 
vertebrae behind the heart at a dose of 1.80 Gy. Due to techno-
logical advances, modern medicine can accurately implement 
this prescription. 
 The radiation dose prescribed by the physician can be deliv-
ered to an accurate point because the target in the body can be 
accurately aimed at using cutting-edge treatment equipment. 
The radiation dose can be precisely predicted through high per-
formance computer calculations based on the patient’s com-
puted tomography images. We can say that the development of 
computer and machine engineering is most acutely applied to 
the treatment of human diseases in the area of clinical cancer 
RT. In addition, the development of cutting-edge imaging tech-
nologies has overcome the limitations of cancer RT in the past, 
when the treatment relied on two-dimensional images. These 
new technologies enable physicians to see more clearly, delin-
eate shapes or outlines that were unclearly identified in the past, 
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provide three-dimensional shapes or location information of 
tumors, and can be fused to planned dose distributions for RT 
with magnetic resonance images at the same locations and co-
ordinates.
 Deepened understanding through biological studies on the 
effects of radiation on human bodies helps reduce radiation 
doses for tumor control through the development of radiation 
sensitizers that increase tumors’ responses to irradiation. Pre-
clinical small animal based transitional studies and molecular 
biological studies of the effects of radiation on normal tissues 
around tumors or damage to the tissues assist in minimizing 
the side effects of RT to maximize patients’ quality of life. 
 In addition, the development of medical physical quality as-
surance (QA) techniques and programs is playing essential and 
pivotal roles in the identification, maintenance, and manage-
ment of accurate and precise RT for cancer patients as well as 
for RT workers’ safety while delivering high-dose radiation for 
tumor treatment to many patients every day. Clinical RT for tu-
mors can continue to develop based on these safety devices. 
This process of development is quickly becoming a base for achi-
eving the ‘optimization’ of medical use of radiation. This issue 
concretely describes the changes in individual elements during 
the development of RT to minimize the effects of radiation on 
normal tissues.
DEVELOPMENT OF CLINICAL RADIATION 
ONCOLOGY AND ITS EFFECTS ON NORMAL 
TISSUES AROUND TUMORS
Although the full story of the development of radiation oncolo-
gy should include the development of all of computer and ma-
chine engineering, cutting-edge imaging technology, studies of 
the effects of radiation on human bodies, and medical physical 
quality assurance programs in a broad sense, in this section, the 
development of clinical radiation oncology in the narrow sense, 
limited to the development of radiation oncology in the clinical 
field and the macroscopic and functional effects of that devel-
opment on normal tissues will be addressed.
 First, the clinical experience and knowledge in the field of 
clinical RT that have been gradually accumulated over time led 
to deepened and concretized knowledge about appropriate ra-
diation dose prescriptions for tumor control, such as appropri-
ate radiation doses for control of certain tumors and how the 
radiation effect can be reinforced to tumors. Recently, a meth-
od to maximize tumor control with extreme hypofractionation, 
called stereotactic ablative body radiotherapy (SABR), has been 
developed and is being widely used (1,2). Experience and knowl-
edge about the radiation dose-volume relationship to macrosco-
pic damage and functional disorders in many organs has also 
accumulated. 
 Furthermore, various prediction models for estimation of re-
lated probabilities have been devised. For instance, tumor con-
trol probabilities (TCP) and normal tissue complication proba-
bilities (NTCP) are obtained through mathematical formulas 
composed of indicators related to tumor control and side effects 
on normal tissues, respectively (3,4). These probabilities become 
important clinical information that enables quantitative judg-
ment on the benefits of (tumor control) and accompanying harms 
(side effects on surrounding tissues), thereby enabling the justi-
fication of the relevant radiation dose prescription when radio-
therapies for cancer patients are planned at clinics.
 For almost all normal organs that may exist around tumors, 
threshold doses are also presented in their own way such as 
TD50/5 (the radiation dose that causes 50% of the patients to 
have radiation-induced complications within 5 years) and TD5/5 
(the radiation dose that causes 5% of the patients to have radia-
tion-induced complications within 5 years). However, these 
models and threshold doses cannot be regarded as sufficiently 
reflecting recent diverse dose fractionation schemes and cut-
ting edge treatment techniques, and should be continuously 
updated. The establishment of these pieces of information en-
ables us to predict the occurrence of side effects more accurate-
ly when we plan radiotherapies, induces us to devise diverse al-
ternative methods that may reduce such side effects, and plays 
the role of a guide to help us not to implement unreasonable 
treatments, with too-high probabilities of the occurrence of side 
effects compared to the probabilities of tumor control. It can be 
said that, compared to the past, more exquisite and safer treat-
ments are implemented now based on these pieces of knowl-
edge.
 As for methods of setting target volumes for tumors of cancer 
patients, in the past, such methods were relatively simple as the 
locations of shields were drawn on skeletal structures on simple 
two-dimensional X-ray planes; current methods are quite com-
plicated and exquisite. They require higher expertise as 3D CT 
images are taken from almost all patients and target volumes 
are drawn on CT cross sections in every slice (5). As knowledge 
and experience have accumulated in clinical radiation oncolo-
gy on the conditions of tumor recurrence after RT, such as re-
currences in the central regions of primary cancers, recurrences 
in the surrounding regions of primary cancers, 1st echelon lymph 
node recurrences, and 2nd echelon lymph node recurrences, 
the volume range of treatment judged to have been excessive in 
the past is gradually decreasing. Since anticancer chemothera-
py has also been developing recently, target volumes are gener-
ally decreasing in cases where diverse multimodality treatments 
combining anticancer chemotherapy and radiation are imple-
mented, so that only macroscopic tumors are treated or only 
macroscopic tumors and adjacent lymph nodes are treated, 
and this means that less radiation is delivered to surrounding 
normal tissues. 
 Image guidance systems to identify the anatomical structures 
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of treatment sites at every time of RT were nonexistent in the 
past. However, recent RT systems have been installed with com-
puterized tomography 3D volume imaging devices so that the 
three dimensional structure of the tumor and surrounding nor-
mal tissues can be identified at each time of treatment as well 
as changes in tumor sizes in the case of some macroscopic tu-
mors. There are cases where tumor sizes decrease rapidly even 
during periods of fractionated RT. For such tumors, the concept 
termed “adaptive radiotherapy” can be introduced to continu-
ously reduce target volumes when tumor sizes have decreased, 
thereby gradually reducing radiation exposure to surrounding 
normal tissues (6,7). For instance, in one case a large small cell 
lung cancer decreased by more than 30% after only the first two 
weeks out of the total treatment period of six weeks. This change 
was immediately noticed and the target volume was revised to 
correspond to adaptive radiotherapy. In another case, the head 
fixing mask of a head and neck cancer patient become loose 
because the outline of the skin of the patient changed due to 
rapid loss of neck edema and body weight. The head fixing mask 
was immediately corrected for accurate treatment under the 
principles of adaptive radiotherapy for administration of more 
accurate doses. 
 This adaptive RT has only become possible due to the intro-
duction of systems that allow for changing complicated treat-
ment designs many times during a treatment process due to in-
creases in the time efficiency of RT plans, something that was 
not even dreamed of in the past. Adaptive RT can be said to be 
different from cone down treatment, which treats only those 
macroscopic tumors that remain after completing radiation ir-
radiation for microscopic tumor control, because of the timing 
of and reasons for readjustment of targets. In fact, we can con-
clude that clinical radiation oncology is a study of setting radia-
tion doses and target volumes for prescriptions. In this case, 
chang ing appropriate radiation doses and target volumes are 
intended to reduce radiotherapy’s side effects. Recently, adap-
tive RT has been developed into a form of actively adjusting 
treatment ranges for tumors that change in size even during RT 
periods.
OPTIMIZATION OF THE EFFECTS OF RADIATION 
ON NORMAL TISSUES FOLLOWING THE 
DEVELOPMENT OF MEDICAL PHYSICS, 
COMPUTERS, AND MACHINE ENGINEERING
Entering the 1990s, the development of medical physics, com-
puters, and machine engineering has been extensive, and this 
development has been naturally incorporated into the field of 
RT to play an important role in minimizing side effects and pro-
tecting normal tissues in treatment ranges. In this section, the 
core part of such development will be explained concretely. 
Dimension change: 2-Dimensional → 3-Dimensional → 
4-Dimensional radiotherapy
Two-dimensional therapy is a method of estimating the loca-
tions of tumors from the front or lateral side of patients based 
on bony structures through kilo voltage (kV) X-ray based plain 
radiographic images. This method is used to apply radiation 
therapy only anterior-posteriorly or laterally. Clinical RT could 
not get out of the frame of this two-dimensional approach to 
therapy for a long time. In the middle of the 1990s, three dimen-
sional (3D) spatial information on patients’ bodies and internal 
organs obtained through computed tomography (CT) became 
available as computerized data. This enabled the implementa-
tion of 3D RT using computers to plan simulated treatments.
 Through the 3D spatial information from CT and Hounsfield 
Unit information obtained from individual tissues, actual radia-
tion doses absorbed in the body could be known. This was sup-
ported by computing ability to calculate the doses, and there-
fore 3D conformal RT was finally introduced into clinics (8). 3D 
conformal RT rapidly diffused immediately after commercial-
ization. 3D conformal RT accurately targets tumors in various 
organs of human bodies. The locations of tumors can be seen at 
diverse angles and from diverse directions as well as sufficiently 
dispersing doses on surrounding normal organs to avoid plac-
ing any important normal organs in danger, thereby enabling 
much safer RT (Fig. 1). 
 Four-dimensional (4D) RT was introduced in 2010 and has 
been ever-spreading. 4D RT means taking the motion due to 
breathing into account in RT plans, such as treatment for tumors 
(e.g., lung cancer) moving due to breathing. RT systems are al-
ways divided into two stages, RT planning and radiation deliv-
ery. 4D RT planning obtains CT images that reflect breathing 
movements, that is, video CT (4D-CT) to plan RT with accurate 
and sufficient information about the movements due to breath-
ing. In the actual stage of radiation irradiation, diverse techni-
ques are used such as basic 4D RT, in which the patient is in-
structed to breathe comfortably or shallowly, and the entire 
movement trajectories of tumors obtained through 4D-CT are 
regarded as tumors and aimed at. Another technique is the Ac-
tive Breathing Control method in which the patient holds his/
her breathe for 10-20 seconds during which the radiation beams 
are applied, to restrict and control the range of movement of 
lung tumors in the lung. 4D-Gating RT monitors respiration 
motion magnitudes using equipment such as ANZAI BeltTM or 
Real-time Position ManagementTM (RPM) to determine a thresh-
old of movements and radiation is administered only when tu-
mors are located in the center of the amplitude, excluding sec-
tions in which the amplitude is too large. 4D-Tracking RT ap-
plies radiation by following the movements of tumors, using 
special equipment such as Cyber-Knife (9). These methods, in 
which movements are sufficiently understood and the move-
ments are restricted or followed, either in the stage of therapy 
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planning or in the stage of irradiation, can be regarded as ad-
vanced therapies that can minimize damage to normal tissues 
around tumors (Fig. 2).
Intensity modulated radiotherapy and multi-leaf 
collimator
Intensity-modulated RT can truly be said to be a revolutionary 
scientific development. If RT made a great leap from 2D thera-
py when 3D conformal RT was introduced, the clinical intro-
duction and commercialization of intensity modulated RT can 
be said to be a leap comparable to or larger than that. The core 
concept of intensity modulated RT is minutely modulating the 
intensities of radiation on the tumor and adjacent surrounding 
normal tissues every time radiation is administered (10). When 
A B C
Fig. 1. Principles and conceptual diagrams of 2D radiotherapy, 3D conformal radiotherapy, and intensity modulated radiotherapy. (A) 2D radiotherapy: Radiation is administered 
only anterior-posteriorly or laterally, precisely based on bone structures so that, when treating concave tumors (T), the distribution of prescribed dose (Dark Yellow) becomes 
rectangular and high dose radiation is focused on the center of the tumor and adjacent normal tissues (N). (B) 3D conformal radiotherapy: The patient’s body is simulated in the 
computer and radiation can be delivered at diverse angles so that radiation doses to normal tissues outside the tumor can be reduced but radiation dose to normal tissues in 
the center of tumors cannot be reduced. (C) Intensity modulated radiotherapy: In the case of intensity modulated radiotherapy, unlike 3D conformal radiotherapy in which single 
direction irradiation can be delivered with only one beam, radiation beams are divided into numerous beamlets to minutely adjust the intensity of radiation. The beams are de-
livered in 360 degree rotations or at diverse angles so that even normal tissues in the center of tumors can be irradiated with lower doses of radiation than the prescribed dose.
N
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Fig. 2. 4D-Radiotherapy concept diagram. (A) Radiotherapy during natural free breathing. In this case, the normal lung tissues in the whole range of the moving Y-axis are irra-
diated. (B) Gated radiotherapy (window period RT). Radiation beams are alternatingly turned on and off according to the patient’s respiration cycle so that radiation is not ad-
ministered during the top and bottom parts of the respiration cycle, thereby excluding some normal tissues from irradiation. (C) Gated radiotherapy with active breath control. 
Although the respiration cycle is followed, radiation is delivered while the patient is holding his/her breath so that relatively small volumes of normal lung tissues are irradiated. 
(D) Tracking radiotherapy. This is the most ideal therapy, in which the patient breathes comfortably, and an image-guided or respiration sensor-based tracking system follows 
the patient’s tumors to only deliver radiation to the tumors. In this method, the least volume of surrounding normal lung tissues is irradiated. However, in this case, quite strict 
quality assurance programs are required because the error tolerance in this irradiation system is very small.
A B
C D
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the therapy is planned, different tumor regions, that is, high dose 
prescription regions and low dose prescription regions can be 
set, and restricted doses can be set for surrounding normal tis-
sues. Thereafter, if the RT planning computer is ordered to gen-
erate a RT plan, an optimum dose distribution will be derived 
through diverse and complicated beam combinations deliv-
ered by the multi-leaf collimator (MLC). For tumor targets, if 
the center of tumors are judged hypoxic and resistant to radia-
tion or are quite densely populated with tumor cells, a higher 
radiation dose can be prescribed. Parts adjacent to macroscop-
ic tumors or regions judged as harboring microscopically in-
vading tumors can be irradiated with a lower dose of radiation 
compared to gross tumors. Doses to surrounding normal tis-
sues can also be limited to those that would not cause any side 
effects. In particular, radiation doses can be restricted very strong-
ly for very sensitive organs. This means that dose distributions 
in the body can be finely modulated. 
 The invention of intensity modulated RT can be said to be 
primarily attributable to the advancement of computer science 
and the development of the computer-controlled MLC that emits 
numerous slices of radiation to enable fine modulation. The 
MLC was first developed as a set of many collimators in the form 
of small strands that were installed on the head of the radiation 
generator to relieve radiologic technicians’ efforts to manually 
insert cerrobend lead block shields for individual directions of 
irradiation for the patient to fit the form of necessary shielding. 
The speed of MLC was not very high at the beginning. However, 
as the thickness of each collimator of a MLC installed on the 
linear accelerator was gradually reduced from 1.5 cm to 1 cm, 
to 0.5 cm, and to 0.3 cm now, the movement speed increased 
so that many fine and diverse slices of radiation can be deliv-
ered and treatment of a patient can be completed in only 10-20 
minutes. 
 The AgilityTM 160-leaf MLC recently introduced to the market 
has 0.5 cm thick collimators that can swiftly move diverse forms 
of radiation beams at speeds of approximately 6.5 cm per sec-
ond in a field size of 40 cm × 40 cm to form excellent dose dis-
tributions, and the TrueBeam STXTM is equipped with 0.25 cm 
thick collimators to enable highly precise treatment. The tomo-
therapy equipment has a Y-axis field limited to 5 cm at the max-
imum but is installed with a binary MLC that rotates helically 
for treatment. The movements of the MLC are air-hydraulically 
modulated at very high speeds to enable very fine modulation 
of radiation intensities. 
 In the case of 3D conformal RT, doses to tumors and surround-
ing normal tissues can be known as resultant values when radi-
ation angles and the intensities of individual beams have been 
determined. In the case of intensity modulated RT, desired dos-
es or dose limits are set and the computer determines the radi-
ation methods by itself (Fig. 1). Since doses desired in the body 
can be more freely modulated, more optimal dose distributions 
can be obtained than with 2D or 3D conformal RT in terms of 
normal tissue protection for most types of cancers. For instance, 
whereas 2D or 3D conformal RT cannot reduce doses to the 
hippocampus that are known to be associated with cognitive 
dysfunction during whole-brain irradiation for metastatic brain 
tumors, intensity modulated RT can reduce doses to the hippo-
campus located in the center of the brain to less than a half of 
surrounding doses so that fewer side effects from brain treat-
ment can be expected (11,12). 
Radiosurgical management
Recently, radiosurgery has been attracting the most attention in 
the field of RT. Radiosurgery is a treatment method that delivers 
high dose radiation of around 10 Gy for each fraction, and there-
fore the radiation needs to applied very precisely and accurate-
ly. The radiation is delivered in many diverse directions to be 
concentrated on the tumor so that absorbed radiation doses for 
surrounding normal tissues are drastically reduced (Fig. 3). As 
RT has become very precise, tumors very close to normal tissues 
can now be treated more safely. This technique has become 
possible through the development of computers, machine en-
gineering, and cutting-edge imaging techniques. This therapy 
has been actively implemented recently in parallel organs (such 
as the lung and liver) and has been reported to have been capa-
ble of obtaining amazing local control rates of 97% for 20 Gy ×  
3 fractions = 60 Gy in early-stage lung cancer (1). 
 This therapy has been actively used for early-stage lung can-
cer, solitary or oligo-metastatic pulmonary cancer, and liver can-
cer. This therapy is also used for fast pain relief and local control 
in patients with vertebral metastasis in cases where spinal cord, 
a serial organ, can be safely excluded. The Gamma-Knife had 
been the most frequently used device for stereotactic radiosur-
gery of benign and metastatic brain tumors before equipment 
dedicated to radiosurgery was commercialized. More recently, 
linear accelerator equipment has been advanced and refined, 
and this equipment is threatening existing radiosurgery through 
smooth incorporation of image-induced techniques. This ther-
apy is usually used only for 3-5 cm or smaller tumors, and re-
quires very careful considerations about surrounding normal 
tissues and strict quality control. 
The dawning of the particle beam therapy age
When discussing the development of radiation oncology, parti-
cle beam radiotherapy, that has been attracting great public at-
tention, cannot be omitted. Unlike for photon beams, in the case 
of particle radiation, due to the nature of radiation beams called 
Bragg’s peaks, lower doses are absorbed at the surface of the 
body and most of the energy is released at a certain depth in the 
body. Therefore, if the depth at which most of the radiation is 
absorbed can be adjusted, radiation can be concentrated on 
tumors and radiation doses to normal tissues the radiation pass-
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es through before arriving at the tumor can be greatly reduced 
(13) (Fig. 4). Although particle beam radiotherapy attracted at-
tention to the extent that it has been called a dream cancer treat-
ment method, it is not yet widely used because the installation 
cost is too high. 
 There are other reasons why this treatment method has not 
yet been widely diffused, not just the high installation cost. Cur-
rently, although photon beam-based radiotherapies are applied 
with excellent image induced and tracking techniques in all 
processes, ranging from RT planning to irradiation, and multi-
fine radiation intensity modulation through MLCs and rotating 
gantry-based diverse angle irradiation systems are smoothly 
implemented, proton therapy has not yet been able to surpass 
the precision of photon beam intensity modulated RT because 
it irradiates only one direction from fixed systems and only in 
two to three directions at the maximum when it uses rotating 
gantries.
 However, recently, in the case of proton particle radiothera-
py, fine intensity modulated particle radiotherapy has been ac-
complished with the introduction of scanning beams, and the 
precision has been enhanced gradually as the number of direc-
tions of radiation has been increased to at least five or six. There-
fore, although it needs time for technical development, proton 
particle radiotherapy is expected to eventually develop into a 
technology that surpasses photon beam therapy. Carbon ion 
therapy is also expected to become a superior therapy because 
it has a relative biological effectiveness approximately three times 
higher than photons or protons. Their Bragg’s peaks have prop-
erties that enable them to deliver lower doses to the skin and 
higher doses to tumors. However, since carbon ions are heavier 
than protons, this therapy requires larger accelerators and much 
higher construction costs than does proton therapy. The tech-
Fig. 3. Stereotactic ablative body radiotherapy (SABR) for a single metastatic lung tumor. The right figure shows the beam configuration of SBRT in which radiation is distributed 
in many diverse directions and the left figure shows the distributions of high-dose radiation confined to the tumor on axial, sagittal, and coronal images.
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Fig. 4. Particle beams and Bragg’s Peaks. Usually, in the case of X-rays (photons), 
the doses are built up on the surface of the skin and absorbed doses are the highest 
at approximately 1-3 cm directly below the skin and attenuated thereafter to become 
gradually lower. On the other hand, particle radiotherapy using particles such as pro-
ton or carbon is characterized by Bragg’s Peaks, in which low absorbed doses are 
administered until a certain depth from the skin and radiation energy is concentrated 
at a certain depth. In this case, if the depth is adjusted well, radiation can be efficient-
ly delivered to tumors with lower doses than normal tissues. Protons are advantageous 
in that radiation energy is almost completely dissipated after the Bragg’s Peak and 
carbon ions are advantageous in that radiation doses are lower than for protons from 
the skin until the radiation arrives at tumors. It is claimed that since carbon radiation 
has approximately three times larger biological effects, carbon ions can enhance treat-
ment efficacy in terms of tumor control.
Choi WH, et al. • Evolving Radiotherapy and Normal Tissue Protection
http://jkms.org  S81http://dx.doi.org/10.3346/jkms.2016.31.S1.S75
nical specifications for rotary gantries and scanning beam ther-
apy need to be developed further before commercialization and 
diffusion of this therapy. 
DECREASES OF THE EFFECTS OF RADIATION ON 
NORMAL TISSUES FOLLOWING THE 
DEVELOPMENT OF RADIOLOGY AND CUTTING-
EDGE IMAGING TECHNOLOGIES
The development of radiology and the incorporation of cutting-
edge imaging technologies brought amazing changes to RT. If 
CT had not been developed, 3D conformal RT and intensity-
modulated RT could not have been developed. CT obtains pa-
tients’ 3D anatomical structural information, and Hounsfield 
Unit (HU) values of CT can be used to accurately predict radia-
tion doses in the body in planning prior to RT. Furthermore, 
image fusion techniques that accurately overlaps CT images, 
that are the basic ones used in RT planning, with MRI and PET 
images when treatments such as 3D conformal RT and intensi-
ty modulated RT are actually implemented, was developed so 
that target volumes can be more accurately drawn. Various can-
cer types, such as brain, prostate, and liver are not well-visual-
ized in CT images but are clearly visible in MRI images. Draw-
ing target volumes on combined images leads to accurate irra-
diation of tumors and also the exclusion of unnecessary normal 
tissues from the range of RT (14). 
 In addition, 4D-CT techniques that can define the trajecto-
ries of tumors following actual breathing, such as in the case of 
a lung cancer that moves according to breathing, by obtaining 
video images instead of still frames have been commercialized 
and actively used at clinics. Accurately grasping tumors’ move-
ments according to breathing helps reduce unnecessary expo-
sure of normal tissues to radiation. The grasping of tumor move-
ments through the fusion of diverse images and 4D-CT is nec-
essary in the stage of RT planning, but in addition, many image-
guided RT techniques have also been developed so that cut-
ting-edge imaging techniques can be applied to the actual pro-
cesses of irradiation to help improve the accuracy and precision 
of treatment. 
 An in-room X-ray based monitoring system (ExacTrac®) can 
be installed in the RT room to identify tumor movements dur-
ing each treatment session within the range identifiable on X-
ray images. RT equipment can be installed with kV CT or mV 
CT so that CT images can be taken in the RT room, when the 
patient is in the treatment posture, immediately before actual 
treatment to recheck the CT when the therapy was planned, 
and the locations of the target and surrounding normal tissues 
defined in the images before treatment. This minimizes the set-
up error that may occur during each session of RT and enables 
adaptive RT. In the cases of tumors moving according to breath-
ing, as mentioned earlier, Active Breathing Control, 4D-gating, 
and tracking treatment are implemented with the help of cut-
ting-edge imaging techniques. Recently, MRI has been installed 
on RT equipment to allow RT to be performed while viewing 
organs in human bodies in real time. This innovation, the View-
RayTM system, was recently developed and just has been com-
mercialized. This equipment is expected to bring about higher 
accuracy to the RT of tumors that cannot be easily seen through 
existing CT but can be viewed more clearly through MRI. 
 Meanwhile, in addition to external radiotherapy, innovations 
in brachytherapy, commonly used to treat prostate cancer, have 
made it possible to insert radioactive isotopes more accurately 
and more precisely by incorporating transrectal ultrasound im-
ages. Recently, attempts to fuse MRI images with ultrasound 
images or CT for initial treatment or post-implant dosimetry 
planning have been made (15,16). In the case of brachytherapy 
for uterine cervical cancer or other high dose rate brachythera-
py, 3D brachytherapy plans using CT or MRI images have been 
widely applied, and finer and safer treatments are being imple-
mented accordingly (17). 
MODULATION OF RADIOTHERAPY-RELATED 
IMPACTS ON NORMAL TISSUES BASED ON 
DEEPENED RADIOBIOLOGICAL UNDERSTANDING 
OF THE EFFECTS OF RADIATION ON HUMAN 
BODIES
When discussing the effects of radiation on normal tissues in 
human bodies during RT for cancer, there is a fact that must be 
always be kept in mind. Although all three major cancer treat-
ment methods (RT, surgical treatment, and anticancer chemo-
therapy) have been proven to be effective for tumor treatment, 
they always involve side effects on normal tissues. Modern med-
icine’s treatments have a limitation in that they cannot remove 
cancer tissues growing in normal tissues without any effect on 
the normal tissues. What is important is to what degree the side 
effects can be reduced while still removing the cancers. 
 Surgery, anticancer chemotherapy, and RT have different 
purposes and primarily cooperate with each other under the 
principle of multidisciplinary treatment in order to cure a pa-
tient’s cancer, but in some cases they compete with each. Sur-
gery is more invasive than RT, can in many cases have much 
more serious adverse effects than the side effects induced by 
RT, and in many cases is inferior to RT in terms of the quality of 
life. For instance, in the case of prostate cancer, RT has much 
lower rates of side effects such as urinary incontinence and sex-
ual dysfunction in comparison to surgery. In the case of laryn-
geal cancer, RT can preserve the voice, but radical surgery can-
not. Surgery is a treatment that should remove the entire organ 
in which a certain cancer exists or the tumor and a considerable 
part of surrounding normal tissues, leading to the complete loss 
of the shape or function of the organ in many cases. 
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 Meanwhile, although anticancer chemotherapy is implement-
ed when a cancer has metastasized or is highly likely to metas-
tasize, or when that type of primary cancer responds very well 
to anticancer chemotherapy, the anticancer drugs that go into 
the body through intravascular injection or oral administration 
cause many systemic side effects such as hair loss, stomatitis, 
digestive organ mucous membrane inflammations, vomiting, 
and declines in the functions of the bone marrow. RT is advan-
tageous in that it is less invasive compared to surgery, is more 
local compared to anticancer chemotherapy, involves the least 
discomfort or pain during treatment periods, and in general 
enhances the quality of life the most. The most important thing 
in cancer treatment is that gains from the treatment are much 
larger than losses due to the treatment.
 The effects of radiation on human bodies are largely divided 
into deterministic effects and stochastic effects (18). Determin-
istic effects refer to effects in cases where there are threshold 
doses of radiation for damage caused by radiation and the level 
of damage increases as the dose increases. The normal organ 
damage values such as TD5/5 and TD50/5 mentioned above 
are reference values of radiation doses for deterministic effects. 
Deterministic effects show distinctive conditions by organ, and 
cataract of eye lenses, vertebral nerve damage, small bowel stric-
ture, salivary gland damage, and pulmonary fibrosis are some 
deterministic effects having threshold doses. In other words, 
this means that such aftereffects will not occur if the threshold 
doses are not exceeded. 
 The introduction of radiation into medicine or human indus-
tries has a history exceeding one century, and radiation has been 
used in many diverse areas. Radiation biology, the study of the 
effects of radiation on organisms, has been ongoing for a long 
period of time, correlating with the history of radiation used for 
examination of human diseases and cancer treatment. Howev-
er, traditional radiation biology is not sufficiently informed with 
the molecular biological knowledge that has been developing 
rapidly recently. In particular, basic molecular biological stud-
ies on the effects of radiation on human bodies are extremely 
insufficient in the area of modern RT dose-fractionation sche-
mes that have recently become diverse and complex, and have 
come to have different trends of dose prescriptions. One of im-
portant reasons for this is that small animal disease models close-
ly reflecting the effects of radiation on human bodies have been 
lacking in terms of modern clinical RT doses and techniques. 
 To mimic local RT for humans in small animals, micro-beam 
irradiation in mm units and image-guiding devices to define 
the treatment are necessary, but there have been difficulties in 
the application of these technologies to small animals. As the 
importance of RT has increased and attention to RT has become 
higher than ever before, efficient small animal-based transition-
al studies on the effects of RT on normal tissues have begun only 
recently. These studies will play a major role in understanding 
RT related side effects on normal tissues more deeply and help 
in developing appropriate treatment methods (19,20). If the side 
effects of RT are biologically overcome, relatively more radiation 
can be delivered to tumors, and this will eventually enhance 
therapeutic ratios. Although only a few drugs (e.g., amifostine) 
have been developed to prevent and relieve the side effects of 
RT’s, more efficient therapeutic agents should be developed 
through further studies.
 Stochastic effects are the effects of radiation on human bod-
ies with no threshold dose or very low threshold doses, and are 
defined to have after-effects of which the seriousness is not pro-
portional to doses but the incidence is proportional to doses. 
These are effects on human bodies that are mainly observed in 
very low dose areas that are far away from clinical RT dose ar-
eas. These effects are often due to the effects of radiation on genes 
and carcinogenesis. Although radiation is recognized as a car-
cinogen, the evidence for radiation to directly cause cancers is 
weak, and radiation is classified as a weak carcinogen. 
 The grounds for arguments that radiation causes cancers rely 
on cohort studies of survivors of the nuclear bombing on Hiro-
shima in Japan, in which exposure to radiation and the frequen-
cy of cancer onset are related to each other in a proportional re-
lationship between radiation dose and cancer incidence rate. 
However, if the risk of secondary cancers in cancer patients re-
ceiving high dose RT at clinics is calculated based on the formu-
la of the dose-response relationship obtained from the above re-
ports, much higher cancer rates are estimated compared to sec-
ondary cancers actually found at RT clinics. This means that the 
risk for cancers caused by radiation is excessively exaggerated. 
 It is very difficult to directly prove that a cancer has occurred 
after RT because of the RT in a cancer patient, because cancers 
are caused by stepwise variations of genes and composite inter-
actions between genes, and changes in microenvironments for 
tumors should accompany the interactions. A single factor such 
as radiation exposure cannot be regarded as the only factor caus-
ing the onset of a cancer. The occurrence of additional second-
ary cancers in cancer patients may not be attributable to RT but 
may be attributable to the patients’ genetic predisposition, im-
munodeficiency, common carcinogenic influence, or other en-
vironmental factors or interactions between these factors and 
RT (21). 
 In fact, although there are many papers claiming an associa-
tion between RT and cancer onsets, there are also reports argu-
ing that there is no association or very little association between 
the two, indicating that this matter requires careful attention. 
Recently, Koshy et al. (22) reported one of the largest studies to 
examine the role of RT for Stage I and II Hodgkin disease, in-
cluding SEER data based on long-term follow-ups of 12,247 
Hodgkin patients. Their conclusion was that the rate of second-
ary malignancy did not increase at all among patients who re-
ceived RT in addition to anticancer chemotherapy compared to 
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patients who had not received RT. Welte et al. (23) reported that 
according to follow-up data from 15,449 patients who received 
RT from 1981 to 2003, the incidence rates of secondary cancers 
not related to primary cancers were just 0.5% and 2.2% in the 
5th year and the 15th year, respectively. Doi et al. (24) reported 
that the probability of occurrence of secondary cancers later in 
children who received RT per 1 Gy of radiation dose was much 
lower compared to children who survived atomic damage. Zel-
efsky et al. (25), who surveyed the occurrence of secondary can-
cers after RT in 2,658 prostate cancer patients, reported that af-
ter compensating for the patients’ ages and smoking history, 
the secondary cancer incidence rate of RT patients was not dif-
ferent from that of patients who had surgery. 
 Given that cancer incidence gradually increased recently, to 
the extent than the probability for a general person to contract 
cancer once during his/her life has been reported to be up to 
25%, the interpretation of cancer development due to radiation 
should be made carefully and objectively. The dispute related 
to the relationship between RT and cancer development will 
continue hereafter. However, separately from this dispute, one 
thing that must be noted and kept in mind when the legitimacy 
of RT for cancer patients is discussed, is that the possibility of 
occurrence of cancers after RT is very low, and even if a cancer 
does occur, it will occur 10-20 years later. Therefore, the use of 
radiographic images to diagnose and evaluate diseases and RT 
for treatment of cancers that threaten life now should be address-
ed separately from the social atmosphere that encourages heal-
thy persons to avoid exposure to radiation. In the case of patients 
with a disease, medical radiographic examinations or cancer 
radiotherapies provide much larger gains than damage due to 
exposure to radiation, unlike in generally healthy persons. There-
fore, the correct perception should be applied when consider-
ing actively undergoing appropriate radiographic examinations 
or radiation treatments when necessary, according to the situa-
tion.
DEVELOPMENT OF MEDICAL PHYSICAL QA 
TECHNIQUES AND PROGRAMS
RT for cancer patients is a complicated process that involves 
many stages. Quality assurance (QA) aims to check the entire 
process carefully, preventing or minimizing errors that may oc-
cur, and effectively improving treatments. When a patient has 
decided to receive RT, the RT begins with taking images of the 
site to be treated, such as CT images, by having the patient as-
sume the posture to be used during actual treatment or by mak-
ing devices to fix certain postures. Thereafter, targets are set on 
the images obtained, and normal organs are drawn on the im-
ages. Then the therapy is planned according to the doctor’s pre-
scriptions to obtain optimum RT dose distributions. During this 
process, what kind of RT planning equipment and RT equip-
ment will be used become important determinants. When the 
RT planning process has been completed, all of these comput-
erized pieces of information are transmitted to the RT room. In 
the RT room, the same posture as the posture taken when the 
therapy was planned is reproduced, the treatment center point 
is identified, and radiation is administered. 
 Immediately before the RT and during the RT, there are pro-
cesses to check whether the RT is implemented properly. Be-
cause RT involves many processes from the moment at which 
RT is determined to be the appropriate treatment, accurate and 
efficient quality control programs are necessary for all of the in-
dividual processes. In particular, thanks to the development of 
RT techniques, normal tissues are exposed to relatively less ra-
diation so that gradually higher-dose radiation can be delivered 
to tumors, to the extent that a one-time dose prescribed for tu-
mors exceeds 20 Gy in some cases. Increases in one-time doses 
per se mean increases in risks and this also becomes a reason 
for the necessity of finer and more accurate QA. If not support-
ed by strict controls, RT cannot be implemented safely and ac-
curately no matter how much it is technologically developed. 
Accurate prediction and measurement of radiation doses ad-
ministered to human bodies without errors is a foundation of 
all radiotherapies. Accurate prediction of radiation doses in min-
ute areas is the basis of safer implementation of high-precision 
RT. Furthermore, the accuracy of the position of RT and the ac-
curacy of dose prediction in organs moving due to breathing 
are extremely important information in actual treatment, and 
doctors can implement RT more confidently based on the in-
formation.
 RT QA is basically divided into periodic QA and patient-spe-
cific QA. Periodic QA consists of machine QA, dose QA, and 
image QA for treatment equipment. This includes QA for the 
therapy planning system that establishes RT plans, treatment 
information systems, treatment equipment, and measuring in-
struments. There is also QA for the process through which indi-
vidual devices are combined to actually deliver radiation. For 
such complicated QA, many recognized institutions such as the 
American Association of Physicists in Medicine (AAPM), the 
ASRO (American Society of Radiation Oncology), the Interna-
tional Commission of Radiation Units & Measurements (ICRU), 
the International Atomic Energy Agency (IAEA), the American 
College of Radiology (ACR), and the European Society of Thera-
peutic Radiation Oncology (ESTRO) provide efficient and safe 
quality control protocols (26-29). 
 Periodic QA can be generally divided into daily, monthly, and 
yearly QA. Daily QA mainly consists of tests of elements that se-
riously affect patients’ setups and individual beam ports’ aim-
ing, equipment doses, and basic safety devices. This QA is in-
tended to prevent serious errors from occurring in patients due 
to wrong treatment procedures. Monthly QA measures detailed 
areas that may become problems through gradual accumula-
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tions of errors over approximately one month, based on the pre-
mise that daily QA of equipment is implemented properly and 
controls for factors that cause systematic errors in many patients, 
although not revealed easily such as beam uniformity. Yearly 
QA conducts measurements comparable to receiving inspec-
tions conducted when equipment is introduced, and careful 
inspections of equipment to check conformity with the therapy 
planning system. According to the results, there may be a need 
to implement maintenance of modeling in the QA or therapy 
planning system. Ideally, all measurements should be conduct-
ed at the level of yearly QA, but this will cause problems in time 
and labor power due to precise measurement. Accordingly, com-
binations of the most ideal frequencies for the maintenance of 
treatment equipment and measuring methods that fit the fre-
quencies are recommended in the form of QA at different fre-
quencies to enable finding the balance between costs and effi-
ciency.
 Recently, surpassing the basic QA in RT processes, individual 
QA has been implemented for the safety of treatments of indi-
vidual patients. This QA can be divided into pre-treatment QA 
that is implemented as end-to-end tests of treatment processes 
before patient specific treatment, and in-vivo measurements to 
evaluate accuracy in the process of actual treatment. This QA is 
intended to secure the safety of treatments of individual patients, 
recognizing the limitations of the hardware and software that 
predict doses actually delivered to patients, and considering 
human factors that may occur. Patient-specific QA means the 
process to check whether the actual radiation delivered is the 
same as the treatment plan for each patient, through therapy 
planning and radiation processes that are the same as those for 
the actual patient but implemented on a human body model 
phantom before treating the patient. In the newest cutting-edge 
treatment methods in which the operation of mechanical de-
vices for radiation irradiation is complicated and exquisite, tar-
get volumes and normal tissues are close to each other, changes 
in doses are large in boundaries, or one-time delivery doses are 
larger than normal fractional doses. To implement these pro-
cesses in all patients, large amounts of manpower and time are 
necessary and investments in this manpower, equipment, and 
time leads to patients’ safety and accurate RT. In the case of high-
precision treatments such as intensity modulated RT and ste-
reotactic body radiation surgery, patient-specific QA needs to 
be implemented in all patients.
 In 2010, the New York Times reported intensity modulated 
RT and other RT related accidents. The full text of the article com-
prehensively addressed human mistakes, machine failure, and 
software problems that lead to so-called catastrophic failure. 
Mentioning the risk of RT that is not properly controlled, this 
article reported that 621 cases of treatment errors occurred in 
the State of New York between 2001 and 2008. As a result, chan-
ges in the paradigm of advanced cutting-edge RT QA were need-
ed (28,30). Accordingly, surpassing the existing quality control 
of related hardware and software, recent QA programs require 
the construction of QA systems based on actual risks in treat-
ment through analysis of failure modes in the entire process. 
Major methods include Failure Mode Effectiveness Analysis 
(FMEA). FMEA analyzes the processes of RT, defining possible 
“Risks” by stage, and analyzing the probability for the risks to 
lead to failure modes (Occurrences), the severity of the failure 
modes, and the ease of detecting the risks through quantitative 
methods to configure radiation treatment safety systems (31,32).
 By now in 2015, RT has undergone great development me-
chanically and systematically as compared to the past, leading 
to improvement in the accuracy of RT and decreases in the fre-
quency of mechanical or human mistakes or errors. In other 
words, while RT equipment or systems in the past had relatively 
more problems compared to those of now, the newest RT equip-
ment has been changed to be excellent in stability and accurate 
in the delivery of prescribed radiation doses. In general, RT is 
implemented now with much lower error rates than in the past. 
However, although the stability of the equipment has become 
excellent as such, and system errors are decreasing, ironically, 
RT QA is becoming more complicated, more time-consuming, 
and more difficult. This is because, although the overall stability 
improved thanks to the introduction of computer systems, high-
ly severe errors appear in forms that cannot be easily detected 
in complicated detailed processes. 
 Meanwhile, RT QA processes have become complicated and 
sophisticated, to the extent that the resultant demand for man-
power and equipment cannot be met. To overcome this prob-
lem, Systematic RTQA programs have been coming to the fore 
recently. These programs are intended to adjust the efficiency 
and safety of RT to achieve balance through treatment process 
analysis methods such as FMEA, using resources available in 
each process of treatment. These programs are intended to con-
trol failure modes occurring in complicated processes most ef-
fectively, even with the restrictions on funds and resources, thr-
ough systematic and appropriate approaches designed by ex-
pert groups. RT and quality control will undergo processes to 
be continuously developed so that accurate radiation doses pre-
scribed can be delivered to tumors and less radiation can be 
delivered to surrounding normal tissues. 
 Recently, various clinical studies have been actively conduct-
ed as domestic multicenter studies or through participation in 
international clinical studies. In these cases, if RT is included in 
the clinical study protocols, the RT should be managed by each 
institution that conducts the study using domestically/interna-
tionally unified protocols and quality control programs. In in-
ternational clinical studies, in the USA, RT quality control is con-
ducted by an institution named Imaging and Radiation Oncol-
ogy Core (IROC, formerly the Radiation Physics Center [RPC]). 
General verification procedures are implemented up to 3D-CRT 
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and in the case of IMRT, Site Specific QA under a concept simi-
lar to Patient Specific QA is added (33). In Europe, RT quality 
control is managed by an institution named Equal Estro (34), 
and in Korea, the Korea Food and Drugs Administration is in 
charge of RT quality control.
CONCLUSION 
RT has been playing important roles in cancer treatment for 
more than one century. From the latter half of the 1990s onward, 
it has been re-writing the history of cancer treatment as new 
cutting-edge treatment methods were poured out with the help 
of the development of medical physics, computers, and machine 
engineering (Fig. 5). The development of RT has allowed for ir-
radiating tumors with higher doses while continuously reduc-
ing the radiation doses delivered to surrounding normal tissues. 
The newest cutting edge radiotherapies are treating tumors with 
amazingly high efficiency that could not be even be dreamt of 
in the past, while minimizing radiation impact on surrounding 
normal tissues. 
 As RT has become more important, along with the advent of 
diverse cutting-edge treatment methods, small animal model 
based radiation biological studies have been developed recent-
ly, and active studies to overcome the side effects accompany-
ing RT through molecular biological mechanisms are in prog-
ress. As RT has become more complicated and finer, precise 
QA is necessary in all procedures from the beginning to the end 
of RT for accurate aiming and the administration of accurate ra-
diation doses. Although errors were maximally reduced through 
periodic QA of equipment or systems in the past, recently, an 
age has come in which RT is implemented while verifying dos-
es according to therapy plans for individual patients. As RT re-
lies on technical development, cutting-edge technologies will 
be continuously developed and the field of radiation cancer 
treatment will continuously develop accordingly. In addition, 
as biological understanding of the effects of RT on surrounding 
normal tissues has become deeper, it is hoped that cancer treat-
ment with no RT-related side effects will be developed some 
day. In an age when 2/3s of cancer patients survive longer than 
five years, and in an age when patients’ quality of life in life after 
treatment is emphasized, it is expected that RT, which is a non-
invasive treatment, can continuously improve the quality of life 
in terms of preservation of organs and functions after treatment.
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Fig. 5. Evolving clinical cancer radiotherapy over a century. Radiation has played important roles in cancer treatment over a long time, more than 100 years. Following the de-
velopment of computers and machine engineering, an age of 3D treatment has come about only in the middle of the 1990s, when 3D conformal radiotherapy began to be dif-
fused widely, and at the beginning of the New Millennium age, cutting edge treatment methods such as IMRT, SBRT, and particle therapy were commercialized and have widely 
diffused, so that the second act of the history of radiation cancer treatment could commence.
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